A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo

NCT07662148 · tracked via the Priya Life Science USA tracker

Sponsor

Biogen

Phase

Phase 1

Started

2026-07-21

Last updated

2026-07-27

Condition(s) studied

Healthy Volunteer

Investigational drug(s) / intervention(s)

BIIB144Placebo

BIIB144: Administered IV

Placebo: Administered IV

Study summary

In this study, researchers will learn how the body processes a study drug called BIIB144. This is a "first-in-human" study. This means that this study drug will be given to people for the first very time in this study. These studies are important because they help researchers learn about the safety of the study drug, how the body processes it, and what dose might be appropriate before testing it in larger groups.

The main goal of this study is to learn more about the safety of a single dose of BIIB144 compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug.

The main question researchers want to answer in this study is:

How many participants have adverse events (AEs) and serious adverse events (SAEs)? An AE is a health problem that may or may not be caused by the study drug.

Researchers will also learn more about:

* How the body processes BIIB144 compared to placebo.

This study will be done as follows:

* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which eligible participants will check into their study research center.
* Participants will stay at their study research center for about 8 days. Afterwards, they will have up to 13 visits to their study research center.
* This will be a "dose escalation" study. In this kind of study, increasing amounts of study drug are given to different groups of participants. Usually, this is done until researchers find the highest dose that does not cause harmful effects. In this study, the number of dose groups and maximum dose are planned in advance. The dose escalation will stop once these planned groups are done or if safety concerns arise.
* There will be a total of 6 groups. In each group, participants will receive a single dose of either BIIB144 or the placebo through an intravenous (IV) needle.
* Throughout the study, participants will give blood and urine samples. Participants will also have physical exams and answer questions about how they are feeling.
* Each participant will be in the study for up to 44 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

55 Years

Healthy volunteers

Accepted

Key Inclusion Criteria: * Have a body mass index (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, at Screening. * Must be in good health as determined by the Investigator, based on medical history and Screening evaluations. Key Exclusion Criteria: * History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator. * History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment. * History of, or ongoing, malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 1 year prior to Day -1). * History of, or positive test result at Screening for, human immunodeficiency virus (HIV). * Any live or attenuated immunization or vaccination given within 14 days prior to Screening, between Screening and Day -1, or planned to be given during the study period. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Primary outcome measure(s)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — Up to Day 280

Trial sites (1)

Facility	City	Region	Status
Las Vegas Clinical Research Unit, PPD Development, LP	Las Vegas	Nevada	Recruiting

More Biogen trials in the USA

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old Active, not recruiting

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec Recruiting

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) Recruiting

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Recruiting

Other trials for the same condition

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants Active, not recruiting

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants Recruiting

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) Recruiting

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07662148 on ClinicalTrials.gov ↗ ← All trials in the USA